Cutaneous T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025
This report can be delivered to the clients within 24 Hours
DelveInsight’s “Cutaneous T-Cell Lymphoma – Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025”report provides an overview of the disease, the comprehensive insights on the competitive landscape and market of Cutaneous T-Cell Lymphoma.
The Report covers detailed historical and forecasted epidemiology of Cutaneous T-Cell Lymphoma(CTCL) in the 7MM (till 2025), segmented on the basis of sub-types (Mycosis fungoides, Sezary syndrome and others i.e., Primary cutaneous peripheral T-cell lymphoma, ATLL, primary cutaneous CD30+ T-cell lymphoproliferative disorders, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and unspecified), gender (predominant in males) as well as stages of the disease (Early Stage and Late Stage).
The Report also includes market trends of the Cutaneous T-Cell Lymphoma for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, and UK) and Japan. The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Cutaneous T-Cell Lymphoma from 2017 to 2025 segmented by seven major markets. In addition, the report also covers market drivers, market barriers and unmet medical need.
The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous T-Cell Lymphoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.
The United States accounts for the highest incident population of CTCL in comparison to EU5 countries and Japan. According to DelveInsight, it is estimated that the incident cases of CTCL in the United States shall increase at a CAGR of 0.35% from 2013 to 2025.
The treatment of CTCL depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The FDA approved drugs are Istodax (romidepsin), Valchlor (mechlorethamine), Uvadex (methoxsalen), Targretin (bexarotene) and Zolinza (vorinostat). The drugs have been considered in our report as per NCCN (United States) guidelines.
Amongst all the 7MM, United States accounts for highest market share for CTCL due to high incidence as well as due to high annual cost of therapy. According to DelveInsight, the Cutaneous T-Cell Lymphoma market size in 7MM is estimated to increase at a compound annual growth rate (CAGR) of 1.6% for the forecasted period i.e., 2013-2025.
SCOPE OF THE REPORT
DelveInsight’s “Cutaneous T-Cell Lymphoma – Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025”report provides an overview of the disease, the comprehensive insights on the competitive landscape and market of Cutaneous T-Cell Lymphoma.
The Report covers detailed historical and forecasted epidemiology of Cutaneous T-Cell Lymphoma(CTCL) in the 7MM (till 2025), segmented on the basis of sub-types (Mycosis fungoides, Sezary syndrome and others i.e., Primary cutaneous peripheral T-cell lymphoma, ATLL, primary cutaneous CD30+ T-cell lymphoproliferative disorders, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and unspecified), gender (predominant in males) as well as stages of the disease (Early Stage and Late Stage).
The Report also includes market trends of the Cutaneous T-Cell Lymphoma for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, and UK) and Japan. The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Cutaneous T-Cell Lymphoma from 2017 to 2025 segmented by seven major markets. In addition, the report also covers market drivers, market barriers and unmet medical need.
The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous T-Cell Lymphoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.
The United States accounts for the highest incident population of CTCL in comparison to EU5 countries and Japan. According to DelveInsight, it is estimated that the incident cases of CTCL in the United States shall increase at a CAGR of 0.35% from 2013 to 2025.
The treatment of CTCL depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The FDA approved drugs are Istodax (romidepsin), Valchlor (mechlorethamine), Uvadex (methoxsalen), Targretin (bexarotene) and Zolinza (vorinostat). The drugs have been considered in our report as per NCCN (United States) guidelines.
Amongst all the 7MM, United States accounts for highest market share for CTCL due to high incidence as well as due to high annual cost of therapy. According to DelveInsight, the Cutaneous T-Cell Lymphoma market size in 7MM is estimated to increase at a compound annual growth rate (CAGR) of 1.6% for the forecasted period i.e., 2013-2025.
SCOPE OF THE REPORT
- Overview of the Global pipeline scenario for Cutaneous T-Cell Lymphoma, products and associated companies information
- Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities.
- The Report provides detailed historical and forecasted epidemiological data of Cutaneous T-Cell Lymphoma in the 7MM i.e., United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2025.
- Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-Cell Lymphoma in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
- To understand the future market competition in the global Cutaneous T-Cell Lymphoma market and Insightful review of the key market drivers and barriers.
- The report will help in developing business strategies by understanding the trends shaping and driving the global Cutaneous T-Cell Lymphoma market.
- Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis
- The Report also covers the detailed historical and forecasted Cutaneous T-Cell Lymphoma market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2025.
Report Introduction
Cutaneous T- Cell Lymphoma Market Overview at a Glance
Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2016
Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2025
Cutaneous T- Cell Lymphoma
Introduction
Types
Causes
Pathophysiology
Symptoms
Diagnosis
Epidemiology of Cutaneous T-Cell Lymphoma
United States
Assumptions and Rationale
Incident Population of Cutaneous T-Cell Lymphoma
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United States
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United States
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States
Europe
Assumptions and Rationale
Germany
Incident Population of Cutaneous T-Cell Lymphoma in Germany
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
France
Incident Population of Cutaneous T-Cell Lymphoma in France
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France
Italy
Incident Population of Cutaneous T-Cell Lymphoma in Italy
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
Spain
Incident Population of Cutaneous T-Cell Lymphoma in Spain
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
United Kingdom
Incident Population of Cutaneous T-Cell Lymphoma in UK
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK
Japan
Incident Population of Cutaneous T-Cell Lymphoma in Japan
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
Treatment Algorithm
International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
United States
NCCN Guidelines
Europe
ESMO Guidelines
Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
EORTC recommendations for the treatment of mycosis fungoides/Seґzary syndrome
Unmet Needs
Competitive Marketed Drug Landscape
Istodax (Romidepsin): Celgene Corporation
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy
Product Profile
Marketed Drug List Continued…
Competitive Pipeline Landscape
Emerging Therapies
Brentuximab Vedotin: Seattle Genetics
Product Description
Research and Development
Product Development Activities
Product Profile
Emerging Drug List Continued
Comparative Analysis
Clinical Stage Products
Pre-Clinical Stage Products
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Domain
Assessment by Stage and Domain
Cutaneous T- Cell Lymphoma: Country-Wise Market Analysis
Total Market Size of Cutaneous T- Cell Lymphoma for 7 MM in 2013-2025
United States
Market Size of CTCL in United States
Stage-Specific Market Size(Early&Late) of CTCL in United States
Europe
Germany
Market Size of CTCL in Germany
Stage-Specific Market Size(Early&Late) of CTCL in Germany
France
Market Size of CTCL in France
Stage-Specific Market Size(Early&Late) of CTCL in France
Italy
Market Size of CTCL in Italy
Stage-Specific Market Size(Early&Late) of CTCL in Italy
Spain
Market Size of CTCL in Spain
Stage-Specific Market Size(Early&Late) of CTCL in Spain
United Kingdom
Market Size of CTCL in United Kingdom
Stage-Specific Market Size(Early&Late) of CTCL in United Kingdom
Japan
Market Size of CTCL in Japan
Stage-Specific Market Size(Early&Late) of CTCL in Japan
Market Drivers
Market Restraints
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Cutaneous T- Cell Lymphoma Market Overview at a Glance
Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2016
Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2025
Cutaneous T- Cell Lymphoma
Introduction
Types
Causes
Pathophysiology
Symptoms
Diagnosis
Epidemiology of Cutaneous T-Cell Lymphoma
United States
Assumptions and Rationale
Incident Population of Cutaneous T-Cell Lymphoma
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United States
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United States
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States
Europe
Assumptions and Rationale
Germany
Incident Population of Cutaneous T-Cell Lymphoma in Germany
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
France
Incident Population of Cutaneous T-Cell Lymphoma in France
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France
Italy
Incident Population of Cutaneous T-Cell Lymphoma in Italy
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
Spain
Incident Population of Cutaneous T-Cell Lymphoma in Spain
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
United Kingdom
Incident Population of Cutaneous T-Cell Lymphoma in UK
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK
Japan
Incident Population of Cutaneous T-Cell Lymphoma in Japan
Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
Treatment Algorithm
International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
United States
NCCN Guidelines
Europe
ESMO Guidelines
Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
EORTC recommendations for the treatment of mycosis fungoides/Seґzary syndrome
Unmet Needs
Competitive Marketed Drug Landscape
Istodax (Romidepsin): Celgene Corporation
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy
Product Profile
Marketed Drug List Continued…
Competitive Pipeline Landscape
Emerging Therapies
Brentuximab Vedotin: Seattle Genetics
Product Description
Research and Development
Product Development Activities
Product Profile
Emerging Drug List Continued
Comparative Analysis
Clinical Stage Products
Pre-Clinical Stage Products
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Domain
Assessment by Stage and Domain
Cutaneous T- Cell Lymphoma: Country-Wise Market Analysis
Total Market Size of Cutaneous T- Cell Lymphoma for 7 MM in 2013-2025
United States
Market Size of CTCL in United States
Stage-Specific Market Size(Early&Late) of CTCL in United States
Europe
Germany
Market Size of CTCL in Germany
Stage-Specific Market Size(Early&Late) of CTCL in Germany
France
Market Size of CTCL in France
Stage-Specific Market Size(Early&Late) of CTCL in France
Italy
Market Size of CTCL in Italy
Stage-Specific Market Size(Early&Late) of CTCL in Italy
Spain
Market Size of CTCL in Spain
Stage-Specific Market Size(Early&Late) of CTCL in Spain
United Kingdom
Market Size of CTCL in United Kingdom
Stage-Specific Market Size(Early&Late) of CTCL in United Kingdom
Japan
Market Size of CTCL in Japan
Stage-Specific Market Size(Early&Late) of CTCL in Japan
Market Drivers
Market Restraints
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
LIST OF TABLES
Table 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025)
Table 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
Table 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
Table 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025)
Table 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Table 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Table 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Table 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Table 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025)
Table 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Table 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Table 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Table 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025)
Table 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Table 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Table 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Table 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Table 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Table 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Table 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Table 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025)
Table 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Table 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Table 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Table 25: Incident Population of Cutaneous T-Cell Japan (2013-2025)
Table 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Table 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Table 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Table 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017
Table 30:Clinical Trials by Recruitment status, 2017
Table 31: Number of Products under development by Companies, 2017
Table 32: Clinical Stage Products, 2017
Table 33: Pre-Clinical Stage Products, 2017
Table 34: Assessment by Monotherapy Products, 2017
Table 35: Assessment by Combination Products, 2017
Table 36: Assessment by Route Of Administration, 2017
Table 37: Assessment by Stage and Route Of Administration, 2017
Table 38: Assessment by Molecule Type, 2017
Table 39: Assessment by Stage and Molecule Type, 2017
Table 40: Assessment by Stage of development and Domain, 2017
Table 41: Recommendations for treatment of CTCL by Radiation Therapy
Table 42: Recommendations for treatment of MF stages IA, IB, and IIA
Table 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma
Table 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025)
Table 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025)
Table 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma inGermany in USD, Million (2013-2025)
Table 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in France in USD, Million (2013-2025)
Table 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025)
Table 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025)
Table 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025)
Table 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025)
Table 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025)
Table 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
Table 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
Table 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025)
Table 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Table 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Table 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Table 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Table 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025)
Table 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Table 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Table 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Table 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025)
Table 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Table 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Table 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Table 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Table 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Table 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Table 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Table 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025)
Table 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Table 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Table 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Table 25: Incident Population of Cutaneous T-Cell Japan (2013-2025)
Table 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Table 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Table 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Table 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017
Table 30:Clinical Trials by Recruitment status, 2017
Table 31: Number of Products under development by Companies, 2017
Table 32: Clinical Stage Products, 2017
Table 33: Pre-Clinical Stage Products, 2017
Table 34: Assessment by Monotherapy Products, 2017
Table 35: Assessment by Combination Products, 2017
Table 36: Assessment by Route Of Administration, 2017
Table 37: Assessment by Stage and Route Of Administration, 2017
Table 38: Assessment by Molecule Type, 2017
Table 39: Assessment by Stage and Molecule Type, 2017
Table 40: Assessment by Stage of development and Domain, 2017
Table 41: Recommendations for treatment of CTCL by Radiation Therapy
Table 42: Recommendations for treatment of MF stages IA, IB, and IIA
Table 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma
Table 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025)
Table 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025)
Table 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma inGermany in USD, Million (2013-2025)
Table 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in France in USD, Million (2013-2025)
Table 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025)
Table 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025)
Table 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025)
Table 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Table 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025)
LIST OF FIGURES
Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025)
Figure 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
Figure 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
Figure 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025)
Figure 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Figure 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Figure 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Figure 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Figure 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025)
Figure 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Figure 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Figure 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025)
Figure 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Figure 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Figure 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Figure 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Figure 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Figure 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Figure 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Figure 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025)
Figure 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Figure 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Figure 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Figure 25: Incident Population of Cutaneous T-Cell Japan (2013-2025)
Figure 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Figure 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Figure 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Figure 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017
Figure 30:Clinical Trials by Recruitment status, 2017
Figure 31: Number of Products under development by Companies, 2017
Figure 32: Clinical Stage Products, 2017
Figure 33: Pre-Clinical Stage Products, 2017
Figure 34: Assessment by Monotherapy Products, 2017
Figure 35: Assessment by Combination Products, 2017
Figure 36: Assessment by Route Of Administration, 2017
Figure 37: Assessment by Stage and Route Of Administration, 2017
Figure 38: Assessment by Molecule Type, 2017
Figure 39: Assessment by Stage and Molecule Type, 2017
Figure 40: Assessment by Stage of development and Domain, 2017
Figure 41: Recommendations for treatment of CTCL by Radiation Therapy
Figure 42: Recommendations for treatment of MF stages IA, IB, and IIA
Figure 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma
Figure 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025)
Figure 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025)
Figure 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma inGermany in USD, Million (2013-2025)
Figure 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in France in USD, Million (2013-2025)
Figure 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025)
Figure 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025)
Figure 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025)
Figure 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025)
Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025)
Figure 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
Figure 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
Figure 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025)
Figure 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Figure 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Figure 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Figure 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
Figure 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025)
Figure 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Figure 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Figure 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025)
Figure 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Figure 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Figure 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
Figure 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Figure 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Figure 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Figure 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
Figure 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025)
Figure 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Figure 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Figure 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
Figure 25: Incident Population of Cutaneous T-Cell Japan (2013-2025)
Figure 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Figure 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Figure 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
Figure 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017
Figure 30:Clinical Trials by Recruitment status, 2017
Figure 31: Number of Products under development by Companies, 2017
Figure 32: Clinical Stage Products, 2017
Figure 33: Pre-Clinical Stage Products, 2017
Figure 34: Assessment by Monotherapy Products, 2017
Figure 35: Assessment by Combination Products, 2017
Figure 36: Assessment by Route Of Administration, 2017
Figure 37: Assessment by Stage and Route Of Administration, 2017
Figure 38: Assessment by Molecule Type, 2017
Figure 39: Assessment by Stage and Molecule Type, 2017
Figure 40: Assessment by Stage of development and Domain, 2017
Figure 41: Recommendations for treatment of CTCL by Radiation Therapy
Figure 42: Recommendations for treatment of MF stages IA, IB, and IIA
Figure 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma
Figure 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025)
Figure 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025)
Figure 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma inGermany in USD, Million (2013-2025)
Figure 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in France in USD, Million (2013-2025)
Figure 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025)
Figure 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025)
Figure 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025)
Figure 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
Figure 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025)
